1. Composite efficacy parameters and predictors of hypoglycaemia in basal‐plus insulin therapy—a combined analysis of 713 type 2 diabetic patients. Issue 3 (17th September 2013) Authors: Seufert, J.; Brath, H.; Pscherer, S.; Borck, A.; Bramlage, P.; Siegmund, T. Journal: Diabetes, obesity & metabolism Issue: Volume 16:Issue 3(2014:Mar.) Page Start: 248 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV‐wiss database. Issue 5 (July 2014) Authors: Laubner, K.; Molz, K.; Kerner, W.; Karges, W.; Lang, W.; Dapp, A.; Schütt, M.; Best, F.; Seufert, J.; Holl, R. W. Journal: Diabetes/metabolism research and reviews Issue: Volume 30:Issue 5(2014:Jul.) Page Start: 395 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Issue 8 (7th June 2016) Authors: Rodbard, H. W.; Seufert, J.; Aggarwal, N.; Cao, A.; Fung, A.; Pfeifer, M.; Alba, M. Journal: Diabetes, obesity & metabolism Issue: Volume 18:Issue 8(2016) Page Start: 812 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta‐analysis of seven phase III trials. Issue 7 (28th January 2016) Authors: Seufert, J.; Bailey, T.; Barkholt Christensen, S.; Nauck, M. A. Journal: Diabetes, obesity & metabolism Issue: Volume 18:Issue 7(2016) Page Start: 721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials. Issue 7 (8th February 2016) Authors: Vora, J.; Seufert, J.; Solberg, H.; Kinduryte, O.; Johansen, T.; Hollander, P. Journal: Diabetes, obesity & metabolism Issue: Volume 18:Issue 7(2016) Page Start: 716 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Sustain 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes. (September 2018) Authors: Bellary, S.; Jodar, E.; Seufert, J.; Damgaard, L.H.; Holst, A Gaarsdal; Leiter, L. Journal: Atherosclerosis Issue: Volume 34(2018) Page Start: e6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The extra‐pancreatic effects of GLP‐1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Issue 8 (16th January 2014) Authors: Seufert, J.; Gallwitz, B. Journal: Diabetes, obesity & metabolism Issue: Volume 16:Issue 8(2014:Aug.) Page Start: 673 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. TRANSCRIPTIONAL AND GENOMIC INTRA‐TUMOR HETEROGENEITY DRIVES SUBCLONE SPECIFIC DRUG RESPONSES IN DIFFUSE LARGE B CELL LYMPHOMA. (12th June 2019) Authors: Roider, T.; Frauhammer, F.; Seufert, J.; Bordas, M.; Stolarczyk, M.; Rabe, S.; Malm, J.; Bruch, P.; Hundemer, M.; Rippe, K.; Goeppert, B.; Seiffert, M.; Brors, B.; Mechtersheimer, G.; Müller‐Tidow, C.; Fröhling, S.; Schlesner, M.; Huber, W.; Anders, S.; Dietrich, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗